Poor
Not Aligned
Patient Risk:
High
Summary
Most claims are not supported by the provided FDA label excerpts (notably multiple patient assistance/discount program and pricing claims). Only the general immunotherapy mechanism is partially consistent with available label text.
Category Scores
Accurate Statements
Keytruda is an immunotherapy that works by boosting the body's natural defenses to fight cancer cells.
Partially supported by 12.1 Mechanism of Action describing pembrolizumab as a monoclonal antibody that blocks PD-1 interaction with PD-L1/PD-L2, releasing inhibition of the immune response, including anti-tumor immune response.
Unsupported Statements
Keytruda (pembrolizumab) is a medication used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer.
Not supported by the provided label excerpts (1 INDICATIONS AND USAGE content is not included).
Merck, the manufacturer of Keytruda, offers a patient assistance program (PAP) for patients who are uninsured or underinsured.
No patient assistance program information is included in the provided label excerpts (only general patient counseling text is shown).
The Merck Patient Savings Program offers a $5,000 annual cap on out-of-pocket costs for eligible patients.
No cost-sharing/cap or program specifics are included in the provided label excerpts.
The Merck Co-Pay Program offers a co-pay of $5 for a 30-day supply of Keytruda for eligible patients.
No co-pay amount, duration, or program terms are included in the provided label excerpts.
Patient Access Network (PAN) offers a program that can help patients pay for Keytruda out-of-pocket.
No third-party payment program information is included in the provided label excerpts.
HealthWell Foundation offers a program that can help patients pay for Keytruda copays and coinsurance.
No third-party payment program information is included in the provided label excerpts.
DrugPatentWatch.com offers an online discount card that can help patients save up to 75% on Keytruda.
No discount card details or savings percentages are included in the provided label excerpts.
The DrugPatentWatch.com online discount card is accepted at over 60,000 pharmacies nationwide.
No network/acceptance or pharmacy count details are included in the provided label excerpts.
Some local pharmacies may offer discounts or promotions on Keytruda.
No statement about pharmacy-specific local discounts/promotions is included in the provided label excerpts.
Contradictions
Important Omissions
Contraindications, boxed warnings, dosing/administration details, and safety monitoring/management information were not provided in the available label excerpts, so omissions relevant to safe use cannot be fully assessed against the label.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Multiple claims about patient assistance/discount programs and specific cost-sharing amounts/savings are not supported by the provided label excerpts, which can mislead patients regarding access and expected costs.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Patient assistance/discount and pricing/network claims are not supported by the provided FDA label excerpts; indication details also cannot be verified from the provided label content.
Suggested Improvement
Restrict claims to information directly present in the available FDA label excerpts (e.g., mechanism description from 12.1) and remove or replace non-label-supported financial program/price/network details unless the full label sections (including 1 INDICATIONS AND USAGE and relevant 17 Patient Counseling details, if present) are provided to substantiate them.